We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA’s ANDA Backlog Poses Threat to Generic Marketing Exclusivity
FDA’s ANDA Backlog Poses Threat to Generic Marketing Exclusivity
February 11, 2011
As the FDA’s backlog in reviewing ANDAs continues to grow, generic-drug makers are now facing a situation where they could potentially lose initial marketing exclusivity on their products as a result.